
Aeglea BioTherapeutics AGLE
Annual report 2025
added 02-19-2026
Aeglea BioTherapeutics Total Current Liabilities 2011-2026 | AGLE
Annual Total Current Liabilities Aeglea BioTherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 58.7 M | 54.1 M | 32 M | 14.7 M | 20.1 M | 16.4 M | 18.4 M | 10.2 M | 5.63 M | 3.96 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 58.7 M | 3.96 M | 23.4 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aligos Therapeutics
ALGS
|
21.2 M | $ 8.64 | 8.07 % | $ 85.4 M | ||
|
Allakos
ALLK
|
36.6 M | - | - | $ 28.6 M | ||
|
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
22.1 M | - | -13.39 % | $ 1.45 M | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
5.04 M | $ 3.11 | 5.42 % | $ 265 M | ||
|
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | ||
|
Applied Therapeutics
APLT
|
71.2 M | - | - | $ 8.42 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
200 M | - | - | $ 546 M | ||
|
Cabaletta Bio
CABA
|
50.2 M | $ 3.2 | 2.24 % | $ 322 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
158 M | $ 21.36 | 4.86 % | $ 998 M | ||
|
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | ||
|
Clearside Biomedical
CLSD
|
6.81 M | - | - | $ 25.3 M | ||
|
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | ||
|
Akebia Therapeutics
AKBA
|
163 M | $ 1.47 | 5.0 % | $ 378 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.73 M | $ 2.92 | - | $ 4.81 M | ||
|
Aquestive Therapeutics
AQST
|
47.6 M | $ 4.19 | 2.7 % | $ 448 M | ||
|
Arcutis Biotherapeutics
ARQT
|
130 M | $ 24.12 | -0.37 % | $ 3.07 B | ||
|
Chimerix
CMRX
|
18.4 M | - | - | $ 756 M | ||
|
Concert Pharmaceuticals
CNCE
|
16.1 M | - | - | $ 401 M | ||
|
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | ||
|
Celldex Therapeutics
CLDX
|
51 M | $ 32.59 | 1.09 % | $ 2.16 B | ||
|
Autolus Therapeutics plc
AUTL
|
73.4 M | $ 1.47 | -1.34 % | $ 391 M | ||
|
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M | ||
|
Cidara Therapeutics
CDTX
|
49.6 M | - | - | $ 1.41 B | ||
|
CNS Pharmaceuticals
CNSP
|
4.1 M | $ 2.44 | 11.7 % | $ 1.08 M | ||
|
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
CTI BioPharma Corp.
CTIC
|
81.1 M | - | - | $ 1.2 B | ||
|
Akari Therapeutics, Plc
AKTX
|
12.4 M | $ 4.25 | 8.35 % | $ 286 B | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M |